Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ)

Alnylam Pharmaceuticals (ALNY) stock rose 8.51% on positive RNAi pipeline updates and analyst upgrades. Analysts set price targets ranging from $318 to $455, citing strong clinical data and growth prospects. The company reported $3.71B in trailing revenue, a 92.1% gross margin, and positive EBIT margin of 23.4%.

AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) discontinued a phase 3 trial for Wainua, a combination therapy for ATTR-CM. Analysts debate whether Alnylam Pharmaceuticals (ALNY) can succeed with its RNA silencing drugs in this area. ALNY's drugs are being considered for use with standard TTR stabilizers, targeting the disease through different pathways. The outcome may impact the ATTR-CM market and RNA therapeutics sector.

Alnylam Pharmaceuticals (ALNY) presented new data at ESC Congress 2026, showing consistent clinical benefits of vutrisiran across ATTR-CM patient populations and treatment settings. Additional analyses highlighted the potential of vutrisiran in addressing multisystemic manifestations of ATTR-CM and the consistent treatment effects of RNAi-powered TTR silencing across sexes. The company also presented data on zilebesiran, an investigational RNAi therapeutic for uncontrolled hypertension, showing

Ionis (IONS) and AstraZeneca (AZN) presented full data from a failed trial of Wainua for transthyretin amyloid cardiomyopathy (ATTR-CM). Jefferies sees neutral to negative implications for Alnylam (ALNY), which is developing similar drugs. ALNY shares closed flat, IONS down 2%, and AZN down 1% on Friday. The trial missed its primary goal, raising doubts about ALNY's TTR business.

Alnylam Pharmaceuticals' stock fell 4.9% pre-market as negative data from a competitor's trial raised concerns about its RNA-silencing drug class. Wells Fargo cut its price target to $256. The company also faces competitive pressure and lowered its 2026 revenue guidance in July.

Alnylam Pharmaceuticals (ALNY) shares dropped 6% after AstraZeneca's Phase 3 trial for a silencer drug targeting ATTR-CM failed, showing no improvement in patients already on stabilizer drugs. The results raise concerns about silencer drugs in the competitive ATTR-CM treatment market, which is expected to be worth billions.